Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Differential efficacy of tyrosine kinase inhibitors according to the types of EGFR mutations and agents in non-small cell lung cancer: a real-world study

Fig. 3

Overall survival from the start of 1st line treatment according to the 2nd or further line agents in patients with progressive disease after EGFR TKI. A Exon 19 deletion: 124 patients, others: 96 patients (L858R: 74, uncommon mutations: 17, dual mutations: 5) and (B) Exon 19 deletion: 81 patients, others: 52 patients (L858R: 39, uncommon mutations: 12, dual mutation: 1). Censoring was indicated by vertical lines

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us